News and Events: Latest News
July 1, 2008
Correlogic is granted U.S. Patent Number 7,395,160 for "Quality Assurance — Quality Control for Electrospray Ionization Processes".
The patent covers important quality control methods to help ensure the validity of test results when blood serum is analyzed on a mass spectrometer. It complements two patents issued to Correlogic earlier this year, that broadly relate to quality control methods for laboratory instruments and to QA/QC methods for using biochips to process samples for a mass spectrometer. This patent is particularly timely, as mass spectrometer-based multivariate assays whose accuracy is dependent upon machine performance have begun to enter the clinical diagnostic market.
June 3, 2008
Dr. Paolo Lecchi, Director of Correlogic’s Mass Spectrometry Laboratory, presented Correlogic’s poster, Defining Instrument Performance and Assessing the Reproducibility of Mass Spectrometric Analyses of Complex Samples at the American Society for Mass Spectrometry’s conference on Mass Spectrometry and Allied Topics. The poster details Correlogic’s patent-pending strategy for monitoring and optimizing the performance of mass spectrometers for use in pattern analysis.
In order for mass spectrometry to generate reliable classifications for serum samples, factors such as variability between instruments and across locations, and drift over time must be controlled. Dr. Lecchi and Dr. John Peltier, Correlogic’s Senior Director of Spectrometry, along with a team of Correlogic scientists, devised a novel approach that utilizes a series of compounds to serve as an "artificial standard pattern" (ASP) to monitor and address mass spectrometric reproducibility. The study demonstrated that subtle drift in the ASP across time and instruments could be monitored — supporting the practicality of this method for the evaluation and standardization of MS-based profiling experiments.
May 2008
Correlogic’s corporate website has been awarded two prizes for website design. In May, the website was honored with a 2008 Summit International Creative Design award. In October 2007 the website won a Davey for website design.
The Summit International Creative Award recognizes the creative design in various media. Submissions from over 50 countries are evaluated on the strength of their vision, execution and ability to communicate.
The Davey awards are sanctioned and judged by the International Academy of the Visual Arts, an invitation-only body consisting of leading professionals from media, advertising, and marketing firms. IAVA members include executives from Alloy, Coach, The Ellen DeGeneres Show, Estee Lauder, Fry Hammond Barr, HBO, iNDELIBLE, Wunderman, MTV, Polo Ralph Lauren, Refinery, Sotheby"s Institute of Art, Wired, Yahoo! and others.
February 19, 2008
The U.S. Patent and Trademark Office issued two quality assurance patents to Correlogic, covering biological assays, biochips, and mass spectrometry. A third QA/QC patent has been allowed by the PTO and is expected to issue this spring.
Read the press release.
|
October 2007
Correlogic"s website won a Davey award for website design. The Davey awards are sanctioned and judged by the International Academy of the Visual Arts, an invitation-only body consisting of leading professionals from media, advertising, and marketing firms. IAVA members include executives from Alloy, Coach, The Ellen DeGeneres Show, Estee Lauder, Fry Hammond Barr, HBO, iNDELIBLE, Wunderman, MTV, Polo Ralph Lauren, Refinery, Sotheby"s Institute of Art, Wired, Yahoo! and others.
July 3, 2007
The U.S. Patent and Trademark office issued a second patent to Correlogic entitled "Heuristic Method of Classification" (U.S. 7,240,038). This is a continuation of a prior patent awarded to Correlogic in 2006 (U.S. 7,096,206). The invention described in both patents relates to algorithms that can be used to discover patterns in complex data sets for diagnostic and other purposes. The patented technology broadly covers the analysis of biological samples such as distinguishing between normal and diseased blood serum. This technology is a key element in Correlogic's expansive analytical platform. The issued patent also covers a wide variety of non-diagnostic applications, including the analysis of financial data and other uses.
June 6, 2007
Correlogic and JEOL sign research and development agreement.
Read the press release.
October 23, 2006
Correlogic announces that Mitsui & Company, Ltd. has made a second round investment in Correlogic and entered into a research collaboration with Correlogic for the clinical development of diagnostic tests for ovarian cancer and other diseases for patients in Japan.
Read the press release.
August 22, 2006
The U.S. Patent and Trademark office issued a patent to Correlogic entitled “A Heuristic Method of Classification” (U.S. 7,096,206 B2). The invention encompasses heuristic algorithms for the classification of objects, and is commonly referred to as the Knowledge Discovery Engine®, or KDE™; it is the key element in the company’s software suite, Proteome Quest® which is used to build biologic state computer models. The issued patent also covers a wide variety of non-biological applications, and thus provides a robust foundation for its eventual use outside of clinical diagnostics.
June 2006
The June 2006 issue of the peer-reviewed journal, Biomolecular Engineering, published “Novel technology for rapid species-specific detection of Bacillus spores”. Correlogic's Dr. Brian Mansfield, Dr. Ping Yip and Dr. Ben Hitt, and colleagues from the Charles Stark Draper Laboratory and Tufts University School of Medicine are authors of this paper. Using pyrolysis-micromachined differential mobility spectrometry (DMS) and Correlogic's Proteome Quest® software to provide a fingerprint that identifies each species, researchers were able to distinguish among bacillus species closely related to Bacillus anthracis (the causative agent in anthrax). Results showed over 90 percent accuracy with a sensitivity of detection of 5,000 spores, significantly below the median infectious dose of 8,000 to 10,000 spores and well below the median lethal dose of ~62,000 spores. Few existing rapid detection techniques detect below 100,000 spores. Together with our collaborators we continue to identify an optimal fingerprint that will be present in a spore sample regardless of concentration, growth media, or interferents that may be present.
In a post 9/11 environment, there is urgent need for tools to detect bio-warfare agents with high specificity. The powerful combination of the DMS machine and Correlogic's technology shows promise for portable, near-real-time accurate detection of spores. In a more generalized setting, it may also be possible to detect and identify other harmful bacteria such as the Clostridia, which cause tetanus, diarrhea, botulism and food poisoning.
March 16, 2006
Our work was also presented as a poster “Detection and Differentiation of Bacillus Spores Using Pyrolysis: Differential Mobility Spectrometry and Genetic Algorithms” at the Pittcon Homeland Security and Forensics session, March 16, 2006.
September 15, 2005
The September 15, 2005 issue of the peer-reviewed journal Analytical Chemistry publishes “Species-Specific Bacteria Identification Using Differential Mobility Spectrometry and Bioinformatics Pattern Recognition”. Brian Mansfield, Correlogic’s VP for Research and Development, is one of the two co-first authors, and Correlogic’s Ben Hitt and Ping Yip are also co-authors of the paper. The collaboration involved Charles Stark Draper Labs, Massachusetts General Hospital and others. Scientists used a portable, micromachined differential mobility spectrometer in conjunction with Correlogic's “Hidden Patterns” and Proteome Quest technology, to identify and differentiate between live bacteria based on analysis of the gases given off by the growing bacterial cultures. The results have implications for diagnosis of bacterial infections using breath analysis. Other applications may include detection and identification of microbial growth in building materials and veterinary uses.
August 15, 2005
The U.S. Patent and Trademark Office grants “Hidden Patterns” patent. The invention – a process for using pattern recognition technology to evaluate subtle patterns of molecular changes in a patient’s body -- is at the core of Correlogic’s tests for the early detection of various cancers and other diseases, and at the core of much research underway throughout the field of proteomics. The patent grants broad protection to the spectrum of biological applications, including disease detection, drug efficacy and toxicity, staging, prognosis and others. Read the press release.
June 9, 2005
Correlogic announces that Quest Diagnostics has made an equity investment in Correlogic. Read the press release.
June 2005
The peer-reviewed journal Endocrine-Related Cancer, publishes "Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma," a paper co-authored by Correlogic’s Chief Science officer Ben Hitt, researchers at the NCI/FDA, the Institute of Child Health and Human Development, and others. This research, based on the use of Correlogic’s pattern recognition approach and technology, demonstrated the applicability of pattern discovery and recognition to differential diagnosis of malignant and benign disease. Researchers identified combinations of low molecular weight molecules that could distinguish 100 percent of metastatic pheochromocytomas from benign cases in a blinded validation set. Metastatic lesions occur in up to 36 percent of patients with pheochromocytoma. Currently there is no reliable way to detect or predict which patients are at risk for metastatic pheochromocytoma.
May 15, 2005
At the annual meeting of the American Society of Clinical Oncologists (ASCO) in Orlando Florida, Correlogic made its first major presentation of the results of our breast cancer research with the Clinical Breast Care Project of Walter Reed Army Medical Center. Our poster, “A Serum Pattern Predictive of Breast Cancer” outlined progress in developing a diagnostic blood test, MammoCheck®, for breast cancer. Using sera from 371 women with normal or benign breast conditions and sera from 234 women with invasive cancer, we generated a model that demonstrated 80.5 percent sensitivity and 94.4 percent specificity on a blinded set of 54 normal benign and 41 invasive cancer sera. Our collaboration with Walter Reed Army Medical Center is ongoing.
May 3, 2005
Correlogic announces a research collaboration with the Uniformed Services University of the Health Sciences (USU) and the Henry M. Jackson Foundation for the Advancement of Military Medicine. In two concurrent studies involving up to 2,000 men, the scientific collaborators will expand Correlogic’s research on the use of its “Hidden Patterns” approach and Proteome Quest® pattern recognition technology to detect prostate cancer, and separately, examine whether Correlogic’s approach and technology can be extended to distinguish between indolent and aggressive prostate cancer. The goal is to validate and refine ProstaCheck® blood tests that can more effectively identify prostate cancer, and help determine the appropriate course of treatment. Read the press release
March 2005
The journal, Arthritis and Rheumatism publishes in the March 2005 issue the results of our research, "A Serum Proteomic Approach To Gauging The State Of Remission In Wegener’s Granulomatosis", using Correlogic’s hidden patterns approach and pattern recognition and discovery technology to distinguish active disease from remission in Wegener’s disease patients. This marks the first publication of the application of Correlogic’s approach and technology to detection of non-cancer diseases. The study was performed by Correlogic scientists, scientists from the Johns Hopkins University School of Medicine, the Mayo Clinic, Cleveland Clinic, Boston University School of Medicine, Beth Israel Medical Center, Duke University, University of California at SF, University of Michigan Medical School, and NCI/FDA. By precisely identifying when stable remission is achieved, this approach could help physicians calibrate the use of potentially toxic drug therapy.
March 16, 2005
On March 16, 2005, Correlogic’s Chief Science Officer, Ben Hitt, spoke before the Third Annual IBC Biomarker Pipeline Conference meeting in Boston. Dr. Hitt discussed the "Use of Seromic™ Patterns in Early Detection of Ovarian Cancer."
Archived News
Back to top >
